rational drug design


Also found in: Acronyms.

rational drug design

The study of the shape of molecules in order to determine how they will bind receptors on cells or combine with other molecules. Drug design that is based on molecular shape or architecture is an alternative to blindly testing hundreds of molecules to see if one or more of them will bind cellular or molecular targets.
Mentioned in ?
References in periodicals archive ?
Rib-X said that its RX-04 programme employs a proprietary approach for rational drug design resulting in entirely new families of compounds that have demonstrated efficacy at low, single doses in murine infection models.
Research chemists involved in rational drug design, and clinicians using knowledge-based therapeutics could be interested.
is a privately held, Canadian biopharmaceutical and chemistry-driven rational drug design company focused on the inhibition of quality enzyme targets associated with disease.
Bearsden is a growing biopharmaceutical company with extensive technology in rational drug design, nucleic acid and medicinal chemistry.
Founded in 2009, Nimbus partnered with Schrodinger to invent and apply a physics-based approach that establishes a new standard for rational drug design.
Gleevec(x) is the first cancer treatment to be developed with rational drug design, based on an understanding of how cancer cells work.
Bearsden is a privately held biopharmaceutical company with a broad-based technology in nucleic acid and rational drug design.
However, today it is possible to design highly-specific covalent drugs by systematically applying rational drug design techniques and leveraging the vastly greater availability of structural information on disease targets.
The relationship with OMJPI is part of the Receptos plan to enable strategic partners with Receptos technology and enhance industry efforts to pursue rational drug design for this important class of therapeutic targets.
PolyMedix uses a rational drug design approach to create non-peptide small molecule drug candidates and polymers that mimic the activity of proteins.
This year's topic focused on targeted therapeutics for cancer, which offer the promise of rational drug design based on mechanisms uncovered in the laboratory.
Waves of technological advancements have powered significant evolution in R&D from serendipitous drug discovery, through to rational drug design.

Full browser ?